Krystal Biotech, Inc. (KRYS) Tops Q3 EPS by 21c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
- Why has the market become so unforgiving of AI earnings?
Tweet
Share
E-mailGet Alerts KRYS Hot Sheet
Join SI Premium – FREE
Krystal Biotech, Inc. (NASDAQ: KRYS) reported Q3 EPS of $2.05, $0.21 better than the analyst estimate of $1.84. Revenue for the quarter came in at $127.34 million versus the consensus estimate of $126.77 million.
For earnings history and earnings-related data on Krystal Biotech, Inc. (KRYS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Apple (AAPL) Tops Q4 EPS by 11c, Beats on Revenue, Beats on iPhone sales, Misses China
- Recursion Pharmaceuticals, Inc. (RXRX) Reports In-Line Q3 EPS
- Valspar Corp. (VAL) Misses Q3 EPS by 47c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
